Restart Life Sciences (TSE:HEAL)
:HEAL
Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.14
Previous CloseN/A
Volume800.00
Average Volume (3M)3.65K
Market Cap
C$5.34M
Enterprise ValueC$2.12M
Total Cash (Recent Filing)C$1.65M
Total Debt (Recent Filing)C$245.36K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding59,377,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet (2025)The move to positive equity and relatively low debt in 2025 materially lowers insolvency and refinancing risk over the medium term. This strengthens financing optionality and preserves operational runway, enabling strategic R&D or partnership investments without immediate distress financing.
Rebuilding Asset BaseA meaningful recovery in total assets signals rebuilding of operational capacity and potential productive investments. A stronger asset base supports future commercialization efforts, collateral for funding, and provides a structural foundation for scaling once revenue-generating activities begin.
Reduced Cash Outflow TrendLess severe negative operating and free cash flow versus trough years indicates improving cash discipline and lower burn. If sustained, this structural improvement reduces near-term external funding needs and extends runway, improving the company's ability to execute development milestones.
Bears Say
No Recurring RevenueAbsence of recurring revenue is a core structural weakness: the company lacks an ongoing commercial engine to fund operations. Long-term sustainability depends on developing and commercializing products or securing durable partnerships; until then funding reliance and execution risk remain high.
Persistent Operating LossesConsistent operating deficits and negative free cash flow indicate the business is not yet self-sustaining and will require repeated external capital. This elevates dilution and refinancing risk, constrains strategic flexibility, and can limit investment in commercialization or R&D over the medium term.
Prior Negative Equity PeriodsHistorical negative equity reflects past capital shortfalls and raises concerns about balance-sheet stability. Even with 2025 improvement, prior insolvency periods can hurt creditor confidence, restrict access to debt or favorable financing, and increase the chance of adverse covenant or restructuring outcomes.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.06 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$5.34M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 66 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 59,377,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Technical Analysis
Options Prices
Currently, No data available
---